Investigators compared the histological outcomes of endoscopic submucosal dissection with those of cap-assisted endoscopic mucosal resection.
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
If the current COVID-19 trends persist, the NCI estimates that the pandemic’s impact could threaten the trend of annually decreasing cancer mortality seen in the US since 1990.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Investigators assessed whether recurrent gastroesophageal junction intestinal metaplasia is associated with increased risk for subsequent dysplasia and whether endoscopic treatment lowers this risk if so.
A reduction in urinary citrate levels may be the mechanism underlying the higher incidence of kidney stones in patients taking PPIs, according to investigators.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
The bile acid sequestrant was designed to be maintained in the stomach over an extended period of time where it was expected to intercept bile before it reached the esophagus.
Regular use of proton pump inhibitors is associated with an increased risk for type 2 diabetes.
Acid exposure measured via reflux monitoring can be predicative of a patient’s ability to discontinue PPI use without symptom escalation.
Both cryoballoon and cryospray ablation therapies are effective in eradicating dysplastic Barrett esophagus.
For patients with advanced urothelial cancer treated with atezolizumab, proton pump inhibitor use is a negative prognostic marker.
Coffee, tea, and soda are associated with an increased risk for gastroesophageal reflux symptoms among middle-aged women.
Genomic copy number instability predicted the risk of disease progression among patients with Barrett esophagus years beforehand.
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
Results of a multicenter, retrospective study of per-oral endoscopic myotomy (POEM) for EGJOO suggest that POEM is an effective and safe therapy.
Patients undergoing sleeve gastrectomy sometimes develop gastroesophageal reflux disease, a major risk factor for Barrett’s esophagus; therefore, researchers investigated whether patients with SG have a high rate of BE.
This phase 3 trial examined whether budesonide orodispersible tablets (0.5 mg or 1 mg, twice daily), with ≤48 weeks of treatment, was superior to placebo in maintaining remission of eosinophilic esophagitis.
Investigators sought to determine whether peroral endoscopic myotomy is safe in patients receiving antithrombotic therapy and examined its clinical success and postprocedural rates of GERD.
A team of investigators assessed the potential for use of proton pump inhibitors to affect the risk of COVID-19 infection.